“biO2flow,” Türkiye’s first domestically developed high-flow oxygen therapy (HFO) device, which will offer a new breath of fresh air in Covid-19 treatment, was developed through a collaboration between Biosys, Arçelik, and May Global.
Bio2Flow, a groundbreaking innovation in HFO therapy, prioritizes functionality with its stylish design and ease of use, bringing a fresh perspective to traditional HFO devices. Bio2Flow's integrated nebulizer allows for the simultaneous administration of medication while providing high-flow oxygen therapy. The patient receives both oxygenation and medication simply by breathing, ensuring no interruptions or reductions in the effectiveness of oxygen therapy.
Note
If you have any photos or video footage to support our news story, please share them with us using the information provided on our contact us page.
